Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic

Area of Science:

• Public Health
• Medical Ethics
• Infectious Disease Management

Background:

• The US FDA issued an Emergency Use Authorization (EUA) for remdesivir to treat severe COVID-19.
• Remdesivir distribution raised ethical questions regarding allocation.
• Minnesota sought to establish a clear, ethical distribution process.

Purpose of the Study:

• To develop and present an ethical framework for the allocation of remdesivir.
• To guide the distribution of remdesivir to healthcare facilities and COVID-19 patients.
• To promote transparency and provide a model for other states.

Main Methods:

• Collaboration between the Minnesota Department of Health, Minnesota COVID Ethics Collaborative, and clinical experts.
• Building upon existing ethical guidance for public health emergencies.
• Iterative framework development incorporating emerging data.

Main Results:

• An ethical framework was created for state-wide remdesivir allocation.
• The framework outlines distribution strategies for facilities and individual patients.
• The process involved adapting the framework as new data became available.

Conclusions:

• The Minnesota remdesivir allocation framework provides an ethical approach to drug distribution.
• Sharing the framework development process encourages transparency and aids other states.
• This ethical guidance is crucial for managing scarce resources during public health crises.